Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial-Reference-Cited by-同舟云学术

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial

Published:2019-04-04 Issue:7 Volume:21 Page:1652-1660
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Yang Wenying¹^ORCID,Ma Jianhua²,Hong Tianpei³^ORCID,Liu Ming⁴,Miao Heng⁵,Peng Yongde⁶,Wang Changjiang⁷,Xu Xiangjin⁸,Yang Tao⁹,Nielsen Anne M.¹⁰^ORCID,Pan Lili¹¹,Liu Weihong¹¹,Zhao Weigang¹²

Affiliation:

1. China‐Japan Friendship Hospital Beijing China

2. Nanjing First Hospital Nanjing China

3. Peking University Third Hospital Beijing China

4. Tianjin Medical University General Hospital Tianjin China

5. Second Affiliated Hospital of Nanjing Medical University Nanjing China

6. Shanghai First People's Hospital Shanghai China

7. First Affiliated Hospital of Anhui Medical University Hefei China

8. Fuzhou General Hospital of Nanjing Military Command Fuzhou China

9. Jiangsu Province Hospital Jiangsu China

10. Medical & Science Degludec Portfolio, Novo Nordisk A/S Søborg Denmark

11. Novo Nordisk (China) Pharmaceuticals Co. Ltd Beijing China

12. Peking Union Medical College Hospital Beijing China

Funder

Novo Nordisk A/S

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13703

Reference33 articles.

1. International Diabetes Federation.IDF Diabetes Atlas 8th ed. 2017.http://www.diabetesatlas.org. Accessed November 8 2018.

2. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013

3. Countryeconomy.com. Population China 2013: Increases in Chinese population.2013.https://countryeconomy.com/demography/population/china?year=2013. Accessed November 8 2018.

4. Federation ID.IDF Diabetes Atlas 8th ed. (China report). 2017.https://reports.instantatlas.com/report/view/704ee0e6475b4af885051bcec15f0e2c/CHN. Accessed November 8 2018.

5. 4. Lifestyle Management: Standards of Medical Care in Diabetes—2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus;Diabetes & Metabolism Journal;2024-09-30

2. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial;Diabetes, Obesity and Metabolism;2024-06-22

3. Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins;Internal Medicine Journal;2024-04-05

4. Observation of the Clinical Efficacy and Safety of degludec/insulin aspart Combined with Metformin in Type 2 Diabetes Patients with Poor Blood Sugar Control.;2024-01-29

5. A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China;Clinical Drug Investigation;2023-03-21